These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases. Gilligan PJ; Li YW Curr Opin Drug Discov Devel; 2004 Jul; 7(4):487-97. PubMed ID: 15338958 [TBL] [Abstract][Full Text] [Related]
3. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210 [TBL] [Abstract][Full Text] [Related]
10. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date. Valdez GR CNS Drugs; 2006; 20(11):887-96. PubMed ID: 17044726 [TBL] [Abstract][Full Text] [Related]
11. Siramesine H Lundbeck. Heading C Curr Opin Investig Drugs; 2001 Feb; 2(2):266-70. PubMed ID: 11816842 [TBL] [Abstract][Full Text] [Related]
12. Involvement of CRF but not NPY in the anxiety regulation via NMDA receptors. Wierońska JM; Szewczyk B; Pałucha A; Brański P; Smiałowska M Pol J Pharmacol; 2003; 55(6):1119-24. PubMed ID: 14730109 [TBL] [Abstract][Full Text] [Related]
13. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor. Yamada Y; Mizutani K; Mizusawa Y; Hantani Y; Tanaka M; Tanaka Y; Tomimoto M; Sugawara M; Imai N; Yamada H; Okajima N; Haruta J J Med Chem; 2004 Feb; 47(5):1075-8. PubMed ID: 14971886 [TBL] [Abstract][Full Text] [Related]
14. Potential uses of corticotropin-releasing hormone antagonists. Zoumakis E; Rice KC; Gold PW; Chrousos GP Ann N Y Acad Sci; 2006 Nov; 1083():239-51. PubMed ID: 17148743 [TBL] [Abstract][Full Text] [Related]
15. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of N-terminal lipidated and/or fluorescently labeled conjugates of astressin as corticotropin releasing factor antagonists. Rijkers DT; den Hartog JA; Liskamp RM Bioorg Med Chem; 2004 Oct; 12(19):5099-106. PubMed ID: 15351393 [TBL] [Abstract][Full Text] [Related]
17. Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity. Rijkers DT; Kruijtzer JA; van Oostenbrugge M; Ronken E; den Hartog JA; Liskamp RM Chembiochem; 2004 Mar; 5(3):340-8. PubMed ID: 14997526 [TBL] [Abstract][Full Text] [Related]
18. Small molecule antagonists of the corticotropin releasing factor (CRF) receptor: recent medicinal chemistry developments. Tellew JE; Luo Z Curr Top Med Chem; 2008; 8(6):506-20. PubMed ID: 18397172 [TBL] [Abstract][Full Text] [Related]
19. A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety. Lewis RT; Blackaby WP; Blackburn T; Jennings AS; Pike A; Wilson RA; Hallett DJ; Cook SM; Ferris P; Marshall GR; Reynolds DS; Sheppard WF; Smith AJ; Sohal B; Stanley J; Tye SJ; Wafford KA; Atack JR J Med Chem; 2006 Apr; 49(8):2600-10. PubMed ID: 16610803 [TBL] [Abstract][Full Text] [Related]